| ||Steve Goodison, Ph.D. |
Director, Cancer Research Institute
Tumor Biology Laboratory
Virginia Urquidi, Ph.D. Co-Investigator
C.J. Rosser, M.D. Co-Investigator
Maria Pino, PhD Postdoctoral Scientist
Bongyong Lee, PhD Postdoctoral Scientist
|Steve Goodison, Ph.D. ||Donna Schade |
|Cancer Research Institute |
MD Anderson Cancer Center Orlando
6900 Lake Nona Blvd
Orlando, Florida 32827
|Phone: 407.266.7405 |
Professor Steve Goodison is Director of the Cancer Research Institute at MD Anderson Cancer Center Orlando. He received his B.S. Honors in Biochemistry from Swansea University, UK, and his Ph.D. in Molecular Biology from Oxford University, UK.
The research program we are actively pursuing is broad in its approach, but is focused upon a single goal. That goal is to improve the lot of the cancer patient. Ongoing aims of the research program include better understanding tumor biology, providing candidate genes for use in detection, diagnostic and prognostic signatures, developing novel algorithms for accurate analysis of high-throughput datasets, role of infection in cancer, and functional analysis of specific genes in tumor progression. These aims have spawned numerous innovative tangential projects along the way, but our overall goal is to use the information to develop improved cancer detection assays, and diagnostic/prognostic signatures for use in the clinical setting, and finally to aid the design and implementation of improved therapeutic strategies.
Studies will be focused on the study of three cancer systems: Breast, Prostate, and Bladder. Project plans in each system are described below, but data from each project illuminates the others, and we have parallel technique-based programs that provide data that are applicable across all of these systems.
BREAST CANCER PROGRAM: In order to facilitate more pertinent metastasis studies we have developed defined experimental systems in which the role of candidate genes can be screened and tested. Monoclonal tumor cell lines, some metastatic, some not, are being derived by propagation of single-cell clones from polyclonal breast carcinoma cell lines (MDA-231, MDA-435, MDA-468), previously established from advanced breast tumors. With Japanese colleagues trained in my laboratory, we have also developed a syngeneic breast metastasis model (MHC66) that is revealing an alternative non-invasive mode of metastatic dissemination. These monoclonal cell lines represent an excellent and unique resource with which to enable the screening and testing of genes involved in the progression of human breast cancer cells to a more malignant invasive and metastatic phenotype. Application of differential expression screening methodologies to such well defined experimental systems constitutes a powerful strategy for investigating this topic.
Differential analyses of these resources have provided numerous candidate metastasis-suppressor or -inducing genes. Selected genes are then manipulated in the appropriate clonal cell line for evaluation of a specific role in metastatic propensity. We are currently evaluating candidate genes in tissue microarrays that contain over 2000 cases with available clinical data.
Funding status: Continued model development and majority of the differential analyses are funded by a 5-year NCI RO1 award (PI: S. Goodison). The subtractive immunization and the DNA-aptamer studies are funded by a Susan G. Komen Foundation award (PI: S. Goodison).
PROSTATE CANCER PROGRAM: Our program is aimed at improving the ability to diagnose/prognose prostate disease and in turn, to understand prostate tumor progression mechanisms. The functional role of specific genes in prostate cancer is currently being investigated through genetic manipulation of established cell lines. Another part of our prostate program is the role of chronic infection in prostate tumor progression. This is a controversial topic, but we have evidence that the presence of mycoplasma in the prostate correlates with an aggressive cellular phenotype. We are cloning and characterizing proteins from mycoplasma to study in the laboratory. The plan is to identify small molecule inhibitors that can interfere with the mycoplasma/human cell interface and ameliorate any exacerbating effect on tumor progression. On the human tissue front, we continue to investigate prostate tumor molecular profiles. We have previously developed novel ways to correlate gene expression with cellular phenotype within a heterogeneous tissue mass. We are still validating some of that work with pathology colleagues, but we now have a new program to address this for prostate and breast tissue (see Bioinformatics below).
BLADDER CANCER PROGRAM: In this program our initial objective is to find sets of molecular characteristics which can more reliably and accurately detect early bladder cancer in non-invasively obtained urine. If we can develop detection assays that ultimately lead to a reduction in the incidence of intrusive and expensive cystoscopy at the clinic, then we will have achieved advances that help both the patient and the health system.
We are currently defining molecular signature(s) of bladder cancer based on transcriptional (exfoliated urothelia) and soluble proteomic expression profiles. Molecular data are being acquired from samples obtained from patients of known clinical status and data are being correlated with morphological and clinical parameters. The elucidation of bladder tumor-associated molecular profiles should also increase our understanding of bladder tumor biology which will in turn improve our ability to treat and manage bladder cancer.
Funding status: This program is funded by a 5-year NCI RO1 (PI: S Goodison) and a Florida State James and Esther King Team Science Award (PI: CJ Rosser).
Zhang K, Sefah K, Tang L, Zhao Z, Zhu G, Ye M, Sun W, Goodison S, Tan W: A novel aptamer developed for breast cancer cell internalization. ChemMedChem 2012, 7:79-84.
Watanabe T, Hashimoto T, Sugino T, Soeda S, Nishiyama H, Morimura Y, Yamada H, Goodison S, Fujimori K: Production of IL1-beta by ovarian cancer cells induces mesothelial cell beta1-integrin expression facilitating peritoneal dissemination. J Ovarian Res 2012, 5:7.
Urquidi V, Rosser CJ, Goodison S: Molecular Diagnostic Trends in Urological Cancer: Biomarkers for Non-Invasive Diagnosis. Curr Med Chem 2012, (In Press).
Urquidi V, Kim J, Goodison S, Chang M, Dai Y, Rosser CJ: VEGF, CA9 and Angiogenin as Urinary Biomarkers for Bladder Cancer Detection. Urology 2012, (In Press).
Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, Lubman DM, Goodison S: Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res 2011, 17:3349-3359.
Urbanek C, Goodison S, Chang M, Porvasnik S, Sakamoto N, Li CZ, Boehlein SK, Rosser CJ: Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer. BMC Cancer 2011, 11:233.
Sippel KH, Venkatakrishnan B, Boehlein SK, Sankaran B, Quirit JG, Govindasamy L, Agbandje-McKenna M, Goodison S, Rosser CJ, McKenna R: Insights into Mycoplasma genitalium metabolism revealed by the structure of MG289, an extracytoplasmic thiamine binding lipoprotein. Proteins 2011, 79:528-536.
Sankpal UT, Goodison S, Abdelrahim M, Basha R: Targeting Sp1 transcription factors in prostate cancer therapy. Med Chem 2011, 7:518-525.
Lee CY, Marzan D, Lin G, Goodison S, Silletti S: alpha2 Integrin-Dependent Suppression of Pancreatic Adenocarcinoma Cell Invasion Involves Ectodomain Regulation of Kallikrein-Related Peptidase-5. J Oncol 2011, 2011:365651.
Jia Z, Wang Y, Sawyers A, Yao H, Rahmatpanah F, Xia XQ, Xu Q, Pio R, Turan T, Koziol JA, et al: Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Res 2011, 71:2476-2487.
Huo Q, Colon J, Cordero A, Bogdanovic J, Baker CH, Goodison S, Pensky MY: A facile nanoparticle immunoassay for cancer biomarker discovery. J Nanobiotechnology 2011, 9:20.
Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S, Rosser CJ: Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Urol Oncol 2011, 29:421-429.
Xie X, Feng S, Vuong H, Liu Y, Goodison S, Lubman DM: A comparative phosphoproteomic analysis of a human tumor metastasis model using a label-free quantitative approach. Electrophoresis 2010, 31:1842-1852.
Sun Y, Urquidi V, Goodison S: Derivation of molecular signatures for breast cancer recurrence prediction using a two-way validation approach. Breast Cancer Res Treat 2010, 119:593-599.
Sun Y, Todorovic S, Goodison S: Local-learning-based feature selection for high-dimensional data analysis. IEEE Trans Pattern Anal Mach Intell 2010, 32:1610-1626.
Sun Y, Cai Y, Mai V, Farmerie W, Yu F, Li J, Goodison S: Advanced computational algorithms for microbial community analysis using massive 16S rRNA sequence data. Nucleic Acids Res 2010, 38:e205.
Rosser CJ, Goodison S: Today's discoveries to tomorrow's care: cancer biomarkers revisited. Foreword. Biomark Med 2010, 4:491-493.
Rosser CJ, Goodison S: CD24, a promising biomarker in NSCLC. Biomark Med 2010, 4:495.
Rosser CJ, Goodison S: From gene to protein expression: improving prognostication of DCIS. Biomark Med 2010, 4:496-497.
Rosser CJ, Goodison S: Novel approach for oral cancer biomarker discovery. Biomark Med 2010, 4:495-496.
Goodison S, Sun Y, Urquidi V: Derivation of cancer diagnostic and prognostic signatures from gene expression data. Bioanalysis 2010, 2:855-862.
Villicana P, Whiting B, Goodison S, Rosser CJ: Urine-based assays for the detection of bladder cancer. Biomark Med 2009, 3:265.
Sun Y, Goodison S: Optimizing molecular signatures for predicting prostate cancer recurrence. Prostate 2009, 69:1119-1127.
Sippel KH, Robbins AH, Reutzel R, Boehlein SK, Namiki K, Goodison S, Agbandje-McKenna M, Rosser CJ, McKenna R: Structural insights into the extracytoplasmic thiamine-binding lipoprotein p37 of Mycoplasma hyorhinis. J Bacteriol 2009, 191:2585-2592.
Sakai Y, Goodison S, Kusmartsev S, Fletcher B, Eruslanov E, Cao W, Porvasnik S, Namiki K, Anai S, Rosser CJ: Bcl-2 mediated modulation of vascularization in prostate cancer xenografts. Prostate 2009, 69:459-470.
Sakai Y, Goodison S, Cao W, Urquidi V, Namiki K, Porvasnik S, Urbanek C, Rosser CJ: VEGF induces expression of Bcl-2 and multiple signaling factors in microvascular endothelial cells in a prostate cancer model. World J Urol 2009, 27:659-666.
Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, Young PR, Parker AS, Goodison S: Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev 2009, 18:444-453.
Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, Urbanek C, Wong D, Goodison S, Rosser CJ: Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009, 69:1460-1469.
Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, Reyes L, Sakamoto N, Rosser CJ: Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One 2009, 4:e6872.
Layton T, Stalens C, Gunderson F, Goodison S, Silletti S: Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion. Am J Pathol 2009, 175:2625-2636.
Koziol JA, Feng AC, Jia Z, Wang Y, Goodison S, McClelland M, Mercola D: The wisdom of the commons: ensemble tree classifiers for prostate cancer prognosis. Bioinformatics 2009, 25:54-60.
Goodison S, Rosser CJ, Urquidi V: Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Rev Proteomics 2009, 6:507-514.
Feng S, Yang N, Pennathur S, Goodison S, Lubman DM: Enrichment of glycoproteins using nanoscale chelating concanavalin A monolithic capillary chromatography. Anal Chem 2009, 81:3776-3783.
Eiseler T, Doppler H, Yan IK, Goodison S, Storz P: Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res 2009, 11:R13.
Bandyopadhyay N, Kahveci T, Goodison S, Sun Y, Ranka S: Pathway-BasedFeature Selection Algorithm for Cancer Microarray Data. Adv Bioinformatics 2009:532989.